Greenland Mines Ltd. (NASDAQ: GRML) announced today that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This patent strengthens Greenland Mines' position in the biotech sector, which operates alongside its mining division. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The granting of this patent is significant because it provides robust legal protection for a promising therapeutic approach that could address major unmet medical needs in neurodegenerative diseases. For investors, the expansion of the IP portfolio enhances the company's competitive moat and potential for future licensing or partnership opportunities. For patients and the healthcare industry, the advancement of KLTO-202 to GMP manufacturing signals progress toward clinical trials and eventual regulatory approval, potentially offering new treatment options for conditions like ALS.
To view the full press release, visit https://ibn.fm/x2pHA.
